论文部分内容阅读
目的:探讨奈达铂联合5-氟尿嘧啶对食管癌晚期患者CEA,SCC及临床疗效的影响。方法:收集我院收治的食管癌晚期患者60例,随机分为对照组和实验组,每组各30例,对照组患者给予顺铂+5-氟尿嘧啶的化疗方案,实验组患者给予奈达铂+5-氟尿嘧啶方案化疗。观察并比较两组患者治疗前后血清CEA及SCC水平的变化情况、毒副反应发生率以及临床疗效。结果:与治疗前相比,两组患者治疗后CEA及SCC水平均降低,差异具有统计学意义(P<0.05);与对照组相比,实验组患者治疗后CEA及SCC水平较低,差异具有统计学意义(P<0.05);与对照组比较,实验组患者毒副反应发生率较低,差异具有统计学意义(P<0.05);与对照组比较,实验组患者治疗有效率较高,差异具有统计学意义(P<0.05)。结论:奈达铂联合5氟尿嘧啶能够降低食管癌晚期患者CEA、SCC以及毒副反应发生率,提高治疗效果。
Objective: To investigate the effect of nedaplatin combined with 5-fluorouracil on CEA, SCC and clinical efficacy in patients with advanced esophageal cancer. Methods: Sixty patients with advanced esophageal cancer who were admitted to our hospital were randomly divided into control group and experimental group, with 30 patients in each group. Patients in the control group were treated with cisplatin plus 5-fluorouracil. Patients in the experimental group were given nedaplatin + 5-fluorouracil chemotherapy. The changes of serum CEA and SCC levels, the incidence of toxic and side effects and the clinical effects were observed and compared before and after treatment. Results: The levels of CEA and SCC in both groups were significantly lower than those before treatment (P <0.05). Compared with the control group, the levels of CEA and SCC in the two groups were lower after treatment (P <0.05). Compared with the control group, the incidence of toxic reactions in the experimental group was lower, the difference was statistically significant (P <0.05); compared with the control group, the treatment group patients with high efficiency , The difference was statistically significant (P <0.05). Conclusion: Nedaplatin combined with 5-Fluorouracil can reduce the incidence of CEA, SCC and toxicity in patients with advanced esophageal cancer and improve the therapeutic effect.